Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UroSens Receives Funding and Enters into Clinical Trials

Published: Tuesday, June 18, 2013
Last Updated: Tuesday, June 18, 2013
Bookmark and Share
Board of directors strengthened with key appointments.

UroSens Ltd has announced that it has received £0.5M ($0.8M) investment and has entered into clinical trials to assess the accuracy of its novel UroSens Mcm5-ELISA diagnostic test for the detection of bladder cancer.

The funding has been received from Esperante, a Netherlands-based specialist life sciences venture investment firm, Northstar Ventures’ Finance for Business North East Accelerator Fund, and existing investors.

In addition to the £0.5M investment, UroSens has recently been awarded a grant of £250,000 from the Technology Strategy Board.

The new funding will be used to enable UroSens to carry out a series of clinical studies, which will see the Company working with over 1,200 patients at four leading UK hospitals.

The study is expected to be completed by October 2013. UroSens has secured ethics approval to conduct similar trials for the detection of prostate cancer.

With over 40,000 new cases of prostate cancer and 11,000 of bladder cancer each year in the UK, current diagnostic tests are unreliable, resulting in many unnecessary biopsies.

For both diseases, the UroSens Mcm5-ELISA diagnostic test is expected to significantly reduce the number of patients undergoing these invasive and costly procedures because it offers significantly more accurate diagnostic results.

The new test is based on intellectual property licensed exclusively from Cancer Research Technology (CRT), the technology transfer arm of Cancer Research UK.

The UroSens Mcm5-ELISA test is compatible with established assay technologies and automated platforms and has achieved CE mark as a research use only product, which will allow the product to be commercialized throughout the EU and certain wider markets.

UroSens has also announced two appointments to strengthen its board of directors. Joining the board, effective immediately, are Mr Dean Slagel of Esperante and Dr Alex Buchan of Northstar Ventures.

Dean Slagel has been appointed Non-Executive Director and brings over 20 years of life science industry operational, business development and investing experience.

Alex Buchan has been appointed Board Observer. He joined Northstar in September 2004 following a series of senior commercial roles in the biotechnology sector at companies including Cybersense, Compugen, SDI Europe, EnSys Europe and Archaeus.

Dr Ian Campbell, CEO at UroSens, said: “These are significant steps forward for our company. We are grateful to our existing shareholders, Northstar Ventures and Esperante for the investment. Alongside our successful TSB grant application, this new funding enables us to progress with clinical trials and increase the pace of our commercial development.”

Dr Alex Buchan of Northstar Ventures added: “Bladder cancer is the fifth most common cancer in the UK, with the highest recurrence rate of any malignancy. We are delighted to have invested in UroSens, with its pioneering detection tests and technology, and I look forward to working with the UroSens team.”

Dean Slagel of Esperante commented: “Esperante is delighted to have invested in UroSens, which offers a novel and potentially ground-breaking urological cancer diagnostic being developed under the leadership of an experienced and high calibre management team. We look forward to continuing to support UroSens through to commercialization.”

The Finance for Business North East Accelerator Fund is backed by the European Regional Development Fund and the European Investment Bank.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UroSens Announces Name Change to Arquer Diagnostics Ltd
Rebranding reflects the company's decision to expand into new oncology areas.
Tuesday, July 21, 2015
UroSens Receives £2 Million Investment
Investment will lead to commercialisation of a urine-based diagnostic test for bladder and prostate cancer.
Monday, January 12, 2015
Scientific News
New Tool Could Change How Infectious Diseases Are Diagnosed
Scientists at the University of Utah School of Medicine, ARUP Laboratories, and IDbyDNA, Inc., have developed ultra-fast, meta-genomics analysis software called Taxonomer that dramatically improves the accuracy and speed of pathogen detection.
Grant Supports Project To Develop Simple Test To Screen For Cervical Cancer
UCLA Engineering announces funding from Bill and Melinda Gates Foundation.
Loss Of Y Chromosome Increases Risk Of Alzheimer’s
Men with blood cells that do not carry the Y chromosome are at greater risk of being diagnosed with Alzheimer’s disease. This is in addition to an increased risk of death from other causes, including many cancers. These new findings by researchers at Uppsala University could lead to a simple test to identify those at risk of developing Alzheimer’s disease.
Making Virus Sensors Cheap and Simple
Researchers at The University of Texas at Austin demonstrated the ability to detect single viruses in a solution containing murine cytomegalovirus (MCMV).
Heart Defect Prediction Technology Could Lead to Earlier, More Informed Treatment
Experimental method uses genetics-guided biomechanics, patient-specific stem cells.
Biosensor Detects Molecules Linked to Cancer, Alzheimer's and Parkinson's
Novel biosensor has been proven capable of detecting molecules associated with neurodegenerative diseases and some types of cancer.
Big Data Can Save Lives
The sharing of genetic information from millions of cancer patients around the world could be key to revolutionising cancer prevention and care, according to a leading cancer expert from Queen's University Belfast.
Fast, Simple Test for Colitis
A minimally invasive screening for ulcerative colitis using emerging infrared technology could be a rapid and cost-effective method for detecting disease that eliminates the need for biopsies and intrusive testing of the human body.
Scans Reveal Babies of Mothers with Gestational Diabetes Have More Body Fat
Researchers at Imperial College London have found that the babies born to mothers with gestational diabetes have more body fat at two months of age compared to babies born to healthy mothers.
New Device Could Improve Cancer Detection
UBC researchers develop a microfluidic device to capture circulating tumor cells.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!